SV

Street Verdict

Analyst Scorecard

A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.

“Motilal Oswal is bullish on Symbiotec Pharmalab, with a target price of ₹1,430 against its current market price of ₹1,168, indicating a potential upside of 22%. Its EPS is projected to grow at a CAGR of 23% between FY26 and FY28E, while FY27E RoE is estimated at 10.4%.”

Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%

Symbiotec PharmalabBullishCalled 03 Nov 2026Graded 21 Nov 2026
Verdict:HIT

R4 TARGET_CALL: entered ₹1233.2 on 2026-11-04 (next trading session's close); target ₹1430 reached at close ₹1513.6 on 2026-11-06. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

How it played out

How this is worked out
Time to target
The target was reached on a close 2 trading sessions (2 calendar days) after the entry.
Worst close against it
No close was ever against the call before the target was reached. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Read the original articleSee Motilal Oswal Analysis’s full track record